About: Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond?
Creator	Chuong, Michael Lee, Percy Ning, Matthew Ng, Sylvia Siva, Shankar Mcmahon, Ryan
Source	Medline; PMC; WHO
abstract	PURPOSE: Owing to the coronavirus disease 2019 (COVID-19) pandemic, radiation oncology departments have adopted various strategies to deliver radiation therapy safely and efficiently while minimizing the risk of severe acute respiratory syndrome coronavirus–2 transmission among patients and health care providers. One practical strategy is to deliver stereotactic body radiation therapy (SBRT) in a single fraction, which has been well established for treating bone metastases, although it has been infrequently used for other extracranial sites. METHODS AND MATERIALS: A PubMed search of published articles in English related to single-fraction SBRT was performed. A critical review was performed of the articles that described clinical outcomes of single-fraction SBRT for treatment of primary extracranial cancers and oligometastatic extraspinal disease. RESULTS: Single-fraction SBRT for peripheral early-stage non-small cell lung cancer is supported by randomized data and is strongly endorsed during the COVID-19 pandemic by the European Society for Radiotherapy and Oncology-American Society for Radiation Oncology practice guidelines. Prospective and retrospective studies supporting a single-fraction regimen are limited, although outcomes are promising for renal cell carcinoma, liver metastases, and adrenal metastases. Data are immature for primary prostate cancer and demonstrate excess late toxicity in primary pancreatic cancer. CONCLUSIONS: Single-fraction SBRT should be strongly considered for peripheral early-stage non-small cell lung cancer during the COVID-19 pandemic to mitigate the potentially severe consequences of severe acute respiratory syndrome coronavirus–2 transmission. Although single-fraction SBRT is promising for the definitive treatment of other primary or oligometastatic cancers, multi-fraction SBRT should be the preferred regimen owing to the need for additional prospective evaluation to determine long-term efficacy and safety.
has issue date	2020-06-24(xsd:dateTime)
bibo:doi	10.1016/j.adro.2020.06.011
bibo:pmid	32775790
has license	cc-by-nc-nd
sha1sum (hex)	c621bac815c332d6ac0f172fbb0a31386319f0e3
schema:url	https://doi.org/10.1016/j.adro.2020.06.011
resource representing a document's title	Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond?
has PubMed Central identifier	PMC7406732
has PubMed identifier	32775790
schema:publication	Adv Radiat Oncol
resource representing a document's body	covid:c621bac815c332d6ac0f172fbb0a31386319f0e3#body_text
is schema:about of	named entity 'SBRT' named entity 'Society' named entity 'non-small cell lung cancer' named entity 'determine' named entity 'demonstrate' named entity 'metastases' named entity 'pandemic' named entity 'efficiently' named entity 'Disease' named entity 'PRACTICE GUIDELINES' named entity 'SITES' named entity 'SEVERE' named entity 'SAFETY' named entity 'PERFORMED' named entity 'strategies' named entity 'toxicity' named entity 'COVID-19' named entity 'Radiotherapy' named entity 'severe acute respiratory syndrome' named entity 'health care providers' named entity 'performed' named entity 'risk' named entity 'liver metastases' named entity 'non-small cell lung cancer' named entity 'COVID' named entity 'SBRT' named entity 'prostate cancer' named entity 'COVID-19 pandemic' named entity 'SBRT' named entity 'clinical outcomes' named entity 'SBRT' named entity 'stereotactic' named entity 'Coronavirus Disease 2019' named entity 'data' named entity 'median follow-up' named entity 'COVID-19 pandemic' named entity 'metastases' named entity 'adrenal' named entity 'SBRT' named entity 'tumors' named entity 'MRI' named entity 'prostate cancer' named entity 'SBRT' named entity 'phase II clinical trial' named entity 'SBRT' named entity 'phase II' named entity 'prostate cancer' named entity 'tumors' named entity 'Kidney' named entity 'luminal' named entity 'median follow-up' named entity 'SBRT' named entity 'Centers for Medicare and Medicaid Services' named entity 'liver metastases' named entity 'non-small cell lung cancer' named entity 'survival rates' named entity 'antitumor' named entity 'SBRT' named entity 'liver metastases' named entity 'SBRT' named entity 'SBRT' named entity 'tumor' named entity 'thoracic' named entity 'radiation therapy' named entity 'toxicity' named entity 'follow-up' named entity 'brachytherapy' named entity 'gemcitabine' named entity 'lung tumors' named entity 'brachytherapy' named entity 'SBRT' named entity 'SBRT' named entity 'hazard ratio' named entity 'SARS-CoV-2' named entity 'heterogeneity' named entity 'coronavirus disease 2019'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software